Total Payments
$204,602
2021 Payments
$27,770
Companies
3
Transactions
95
Medicare Patients
3,132
Medicare Billing
$237,105
Payment Breakdown by Category
Consulting$202,930 (99.2%)
Travel$1,135 (0.6%)
Food & Beverage$462.28 (0.2%)
Research$75.00 (0.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $202,930 | 82 | 99.2% |
| Travel and Lodging | $1,135 | 5 | 0.6% |
| Food and Beverage | $462.28 | 7 | 0.2% |
| Unspecified | $75.00 | 1 | 0.0% |
Payments by Type
General
$204,527
94 transactions
Research
$75.00
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $194,930 | 81 | $0 (2021) |
| Bayer HealthCare Pharmaceuticals Inc. | $9,597 | 13 | $0 (2019) |
| Regeneron Pharmaceuticals, Inc. | $75.00 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $27,770 | 30 | Merck Sharp & Dohme LLC ($27,770) |
| 2020 | $14,435 | 16 | Merck Sharp & Dohme Corporation ($14,435) |
| 2019 | $35,322 | 26 | Merck Sharp & Dohme Corporation ($25,650) |
| 2018 | $30,825 | 12 | Merck Sharp & Dohme Corporation ($30,825) |
| 2017 | $96,250 | 11 | Merck Sharp & Dohme Corporation ($96,250) |
All Payment Transactions
95 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $1,535.00 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2021 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Consulting Fee | Cash or cash equivalent | $3,160.00 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2021 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $205.00 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2021 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Consulting Fee | Cash or cash equivalent | $3,215.00 | General |
| Category: ONCOLOGY | ||||||
| 10/04/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $1,020.00 | General |
| Category: ONCOLOGY | ||||||
| 10/01/2021 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Consulting Fee | Cash or cash equivalent | $2,235.00 | General |
| Category: ONCOLOGY | ||||||
| 10/01/2021 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: ONCOLOGY | ||||||
| 09/16/2021 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Consulting Fee | Cash or cash equivalent | $1,495.00 | General |
| Category: ONCOLOGY | ||||||
| 09/16/2021 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $385.00 | General |
| Category: ONCOLOGY | ||||||
| 08/06/2021 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Consulting Fee | Cash or cash equivalent | $1,180.00 | General |
| Category: ONCOLOGY | ||||||
| 08/06/2021 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Consulting Fee | Cash or cash equivalent | $685.00 | General |
| Category: ONCOLOGY | ||||||
| 08/06/2021 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $385.00 | General |
| Category: ONCOLOGY | ||||||
| 08/06/2021 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| Category: ONCOLOGY | ||||||
| 07/01/2021 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Consulting Fee | Cash or cash equivalent | $1,925.00 | General |
| Category: ONCOLOGY | ||||||
| 07/01/2021 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $360.00 | General |
| Category: ONCOLOGY | ||||||
| 06/10/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $1,235.00 | General |
| Category: ONCOLOGY | ||||||
| 06/03/2021 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Consulting Fee | Cash or cash equivalent | $1,205.00 | General |
| Category: ONCOLOGY | ||||||
| 06/03/2021 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $240.00 | General |
| Category: ONCOLOGY | ||||||
| 05/26/2021 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Consulting Fee | Cash or cash equivalent | $420.00 | General |
| Category: ONCOLOGY | ||||||
| 05/26/2021 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $180.00 | General |
| Category: ONCOLOGY | ||||||
| 05/20/2021 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Consulting Fee | Cash or cash equivalent | $1,670.00 | General |
| Category: ONCOLOGY | ||||||
| 05/20/2021 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $420.00 | General |
| Category: ONCOLOGY | ||||||
| 05/20/2021 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $180.00 | General |
| Category: ONCOLOGY | ||||||
| 05/10/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $610.00 | General |
| Category: ONCOLOGY | ||||||
| 04/15/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| AN EXPLORATORY TUMOR BIOPSY-DRIVEN STUDY TO UNDERSTAND THE RELATIONSHIP BETWEEN BIOMARKERS AND INDICATORS OF CLINICAL RESPONSE IN IMMUNOMODULATORY TREATMENT-NAIVE UNRESECTABLE STAGE III IV MELANOMA PATIENTS RECEIVING REGN2810 ANTI-PD-1 | Regeneron Pharmaceuticals, Inc. | $75.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 535 | 6,624 | $290,470 | $34,720 |
| 2022 | 16 | 885 | 15,656 | $688,791 | $70,734 |
| 2021 | 14 | 918 | 13,417 | $620,975 | $71,753 |
| 2020 | 10 | 794 | 10,345 | $467,847 | $59,898 |
Total Patients
3,132
Total Services
46,042
Medicare Billing
$237,105
Procedure Codes
69
All Medicare Procedures & Services
69 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 70553 | Mri scan of brain before and after contrast | Office | 2023 | 36 | 36 | $145,692 | $10,388 | 7.1% |
| 70450 | Ct scan head or brain without contrast | Facility | 2023 | 183 | 191 | $32,513 | $5,987 | 18.4% |
| 70496 | Ct scan of blood vessels of head with contrast | Facility | 2023 | 65 | 65 | $22,485 | $4,185 | 18.6% |
| 70553 | Mri scan of brain before and after contrast | Facility | 2023 | 45 | 46 | $26,588 | $4,050 | 15.2% |
| 70498 | Ct scan of blood vessels of neck with contrast | Facility | 2023 | 59 | 59 | $20,420 | $3,674 | 18.0% |
| 70551 | Mri scan of brain without contrast | Facility | 2023 | 51 | 51 | $19,176 | $2,749 | 14.3% |
| 72148 | Mri scan of lower spinal canal without contrast | Facility | 2023 | 16 | 16 | $5,885 | $941.33 | 16.0% |
| 70491 | Ct scan of soft tissue of neck with contrast | Facility | 2023 | 14 | 14 | $3,854 | $722.04 | 18.7% |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | Office | 2023 | 40 | 6,120 | $6,120 | $686.56 | 11.2% |
| 70544 | Mri scan of blood vessels of head without contrast | Facility | 2023 | 15 | 15 | $3,590 | $684.34 | 19.1% |
| 72141 | Mri scan of upper spinal canal without contrast | Facility | 2023 | 11 | 11 | $4,147 | $652.62 | 15.7% |
| 70553 | Mri scan of brain before and after contrast | Office | 2022 | 77 | 80 | $298,832 | $21,155 | 7.1% |
| 70450 | Ct scan head or brain without contrast | Facility | 2022 | 225 | 231 | $39,795 | $7,257 | 18.2% |
| 70553 | Mri scan of brain before and after contrast | Facility | 2022 | 69 | 70 | $38,675 | $6,170 | 16.0% |
| 70496 | Ct scan of blood vessels of head with contrast | Facility | 2022 | 59 | 59 | $20,849 | $4,177 | 20.0% |
| 72148 | Mri scan of lower spinal canal without contrast | Office | 2022 | 25 | 26 | $46,239 | $4,049 | 8.8% |
| 70498 | Ct scan of blood vessels of neck with contrast | Facility | 2022 | 56 | 56 | $19,775 | $3,719 | 18.8% |
| 70551 | Mri scan of brain without contrast | Facility | 2022 | 66 | 66 | $23,712 | $3,678 | 15.5% |
| 72158 | Mri scan of lower spinal canal before and after contrast | Office | 2022 | 12 | 12 | $42,081 | $3,000 | 7.1% |
| 70551 | Mri scan of brain without contrast | Office | 2022 | 16 | 16 | $36,855 | $2,588 | 7.0% |
| 72141 | Mri scan of upper spinal canal without contrast | Office | 2022 | 12 | 13 | $23,364 | $1,878 | 8.0% |
| 70491 | Ct scan of soft tissue of neck with contrast | Office | 2022 | 19 | 20 | $15,409 | $1,855 | 12.0% |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | Office | 2022 | 86 | 13,770 | $25,770 | $1,590 | 6.2% |
| 72156 | Mri scan of upper spinal canal before and after contrast | Facility | 2022 | 16 | 16 | $8,828 | $1,447 | 16.4% |
| 70544 | Mri scan of blood vessels of head without contrast | Facility | 2022 | 30 | 30 | $7,296 | $1,418 | 19.4% |
About John Chen, MD PHD
John Chen, MD PHD is a Diagnostic Radiology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/04/2005. The National Provider Identifier (NPI) number assigned to this provider is 1376534552.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, John Chen, MD PHD has received a total of $204,602 in payments from pharmaceutical and medical device companies, with $27,770 received in 2021. These payments were reported across 95 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($202,930).
As a Medicare-enrolled provider, Chen has provided services to 3,132 Medicare beneficiaries, totaling 46,042 services with total Medicare billing of $237,105. Data is available for 4 years (2020–2023), covering 69 distinct procedure/service records.
Ad
Practice Information
- Specialty Diagnostic Radiology
- Location Boston, MA
- Active Since 11/04/2005
- Last Updated 12/14/2023
- Taxonomy Code 2085R0202X
- Entity Type Individual
- NPI Number 1376534552
Products in Payments
- KEYTRUDA (Biological) $170,865
- LENVIMA (Drug) $20,040
- MK-1454 (Drug) $470.00
- LIBTAYO (Biological) $75.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Diagnostic Radiology Doctors in Boston
Andrew Kompel, M.d, M.D
Diagnostic Radiology — Payments: $3.4M
Diagnostic Radiology $3.4M
Gregg Miller, M.d, M.D
Diagnostic Radiology — Payments: $3.0M
Diagnostic Radiology $3.0M
Stephan Anderson, M.d, M.D
Diagnostic Radiology — Payments: $2.4M
Diagnostic Radiology $2.4M
Ashraf Thabet, M.d, M.D
Diagnostic Radiology — Payments: $1.7M
Diagnostic Radiology $1.7M
Dr. Mukesh Harisinghani, Md, MD
Diagnostic Radiology — Payments: $1.4M
Diagnostic Radiology $1.4M
Subba Digumarthy, Md, MD
Diagnostic Radiology — Payments: $1.1M
Diagnostic Radiology $1.1M